Posted by Michael Wonder on 01 Oct 2018
Shield Therapeutics announces submission of a new drug application for Feraccru with the US FDA
1 October 2018 - Shield Therapeutics today announces that it has received confirmation from the US FDA of its successful submission of an NDA for Feraccru, Shield’s lead product, which is already approved in the European Union for the treatment of iron deficiency in adults and in Switzerland for the treatment of iron deficiency anaemia in adults with inflammatory bowel disease.
The United States, representing over a third of the global pharmaceutical market, is a very attractive opportunity for Feraccru and a market which Shield retains full ownership of, as well as complete control of the global intellectual property rights.
